Loading…
← CockpitCompetitor Analysis › 2235.HK MicroTech Medical (Hangzhou) Co., Ltd. Class HOpen in the cockpit ↗

MicroTech Medical (Hangzhou) Co., Ltd. Class H2235.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Information Technology›Electronic Equipment/Instruments
Momentum neutral 59
Mkt cap
$353M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$88,307
20-day average traded
Fwd P/E
26.6×
forward earnings
ROIC−WACC
+1.4 pp
WACC 7.1%
Hurdle
-49 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$6.55
1D-1.5%
1W-3.2%
1M-5.0%
3M-6.2%
6M-14.5%
YTD-17.4%
1Y-8.5%
ATR %1.9%
52w lowhigh20.9% off high

What MicroTech Medical (Hangzhou) does

Employees: 664

MicroTech Medical (Hangzhou) at a glance

Size MicroTech Medical (Hangzhou) (2235.HK) is a Hong Kong Information Technology company (Electronic Equipment/Instruments) with a market value of $353M, the 844th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$6.55 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against -24.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 94.8% over the last twelve months (peer median +6.9%); the operating margin is 7.7% (peer median 4.0%).

Valuation It trades at 26.6× forward earnings against a peer median of 15.0× (3rd most expensive of 9).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +53%, so the hurdle is -49 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (7.1% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 20262235.HK 84Peer median 74
Six months, rebased to 100: MicroTech Medical (Hangzhou) against the median of its 20 peers (local-currency closes).

MicroTech Medical (Hangzhou) financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$926MHK$713MHK$372MHK$279MHK$202M
Revenue growth—+92%+33%+38%—
Gross profitHK$522MHK$375MHK$187MHK$124MHK$86.8M
EBITDAHK$88.2MHK$13.4M-HK$150M-HK$215M-HK$154M
Net incomeHK$92.4MHK$43.5M-HK$68.4M-HK$138M-HK$40.8M
Free cash flowHK$33.6M-HK$6.80M-HK$221M-HK$201M-HK$173M
Capital expenditureHK$62.8MHK$42.2MHK$90.2MHK$31.7MHK$34.6M
Total debtn/aHK$102MHK$4.47MHK$9.25MHK$804,138

Quarterly statements and history in the cockpit →

MicroTech Medical (Hangzhou) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%-40%-20%0%7715300275300427300306002278301361600560300266621723236742253590688056300025688071JDG3008132235.HK6-month return →1-month return →
Up and to the right = strong over both horizons. MicroTech Medical (Hangzhou) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×77153002756742253590688056LUCE688071JDG2235.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. MicroTech Medical (Hangzhou) is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%77153002753004273003060022783013616883672323688056300025688071JDG3008132235.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. MicroTech Medical (Hangzhou) is the large dot.

MicroTech Medical (Hangzhou) competitors and peer comparison

How MicroTech Medical (Hangzhou) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MicroTech Medical (Hangzhou) against its 20 peers (data as of 18 Nov 2026)
Measure2235.HKPeer medianRank in peer set
1-month return-5.0%-14.6%4th highest of 21
6-month return-14.5%-24.6%6th highest of 20
Distance from 52-week high-20.9%-45.0%3rd highest of 21
Revenue growth (TTM)+94.8%+6.9%highest of 21
Operating margin7.7%4.0%6th highest of 21
Forward P/E26.6×15.0×3rd most expensive of 9
Growth the price implies (Req g, 7 yrs)4.1%19.3%4th least demanding of 16
Growth delivered (Del g)+53.2%+8.4%highest of 16
Hurdle (Req g minus delivered)-49.0 pp+9.1 ppleast demanding of 16
ROIC minus cost of capital+1.4 pp-4.4 pp3rd highest of 21
EV / EBITDA12.6×9.0×2nd most expensive of 6
Net debt / EBITDA-18.7×0.8×least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
MicroTech Medical (Hangzhou) 2235.HKHong Kong$353M-14%+95%8%26.6×4.1%+53.2%
Nagano Keiki 7715.TJapan$355M+2%+9%12%8.0×-1.8%+8.6%
Chongqing MAS Science & Technology 300275.SZChina$347M-23%-10%7%16.9×24.7%+9.0%
Red Phase 300427.SZChina$361M-54%+13%-15%n/a35.1%-13.7%
Hangzhou Everfine Photo-E-Info 300306.SZChina$364M-27%-3%10%n/a9.3%+0.2%
Shanghai Sk Petroleum & Chemical Equipment 002278.SZChina$365M-37%+2%6%n/a11.7%+3.7%
Ceyear Technologies 301689.SZChina$365Mn/a+17%13%n/an/an/a
SmartGen (Zhengzhou) Technology 301361.SZChina$366M-25%+22%27%n/a7.9%+10.6%
Beijing AriTime Intelligent Control 600560.SSChina$337M-30%+14%1%n/an/an/a
Xingyuan Environment Technology 300266.SZChina$337M-29%-27%-22%n/an/an/a
C.C.P. Contact Probes 6217.TWOTaiwan$336M-65%+26%-4%n/an/an/a
Hefei Gocom Information Technology 688367.SSChina$372M-26%-10%-1%n/a57.2%-1.3%
Cmc Magnetics 2323.TWTaiwan$333M+11%+12%3%n/a2.4%-5.2%
Kyosan Electric Manufacturing 6742.TJapan$331M+11%+4%7%8.0×1.5%+8.4%
NEOSEM 253590.KSSouth Korea$382M-20%-31%5%13.1×n/an/a
Beijing Labtech Instruments 688056.SSChina$326M-6%0%5%59.2×31.6%+2.8%
Hangzhou Huaxing Chuangye Communication Technology 300025.SZChina$383M-9%-16%-22%n/a26.9%-6.5%
Luceco LUCE.LUnited Kingdom$390M-28%+11%11%10.7×7.9%+9.0%
Shanghai W-Ibeda High Tech.Group 688071.SSChina$395M-16%+19%0%58.6×19.3%+11.0%
Judges Scientific JDG.LUnited Kingdom$315M-23%-8%3%18.0×32.4%+12.8%
ZheJiang Tailin Bioengineering 300813.SZChina$315M-29%+19%3%n/a50.9%+11.1%

Questions

Which companies are MicroTech Medical (Hangzhou)'s closest peers?
The cockpit's peer set: Nagano Keiki (7715.T), Chongqing MAS Science & Technology (300275.SZ), Red Phase (300427.SZ), Hangzhou Everfine Photo-E-Info (300306.SZ), Shanghai Sk Petroleum & Chemical Equipment (002278.SZ), Ceyear Technologies (301689.SZ), SmartGen (Zhengzhou) Technology (301361.SZ), Beijing AriTime Intelligent Control (600560.SS).
Is MicroTech Medical (Hangzhou) expensive compared with its peers?
On forward p/e it trades at 26.6× against a peer median of 15.0×, 3rd most expensive of 9 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +53%, so the hurdle is -49 pp: the price already allows for a slowdown.
How has MicroTech Medical (Hangzhou) stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against -24.6% for the median peer; over one year -8.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.